News

On April 2-3, 2025, the VIII International Congress "REPRODUCTIVE HEALTH: A Multidisciplinary Approach in the Continuous Professional Development of Doctors" was held in Kyiv.

The congress was attended by leading experts, scientists, and doctors of various medical fields from Great Britain, Malta, Turkey, Italy, France, and the Netherlands, and the leading gynecological schools of Ukraine were represented - the cities of Kyiv, Dnipro, Kryvyi Rih, Kharkiv, Odessa, Lviv, Poltava, Uzhgorod, Vinnytsia, and Ternopil. The congress program included symposia, clinical consultations, expert discussions, master classes, and simulation trainings.

In his report "Modern approaches to the treatment of vasomotor disorders in menopause" Doctor of Medical Sciences, Professor of the Department of Obstetrics and Gynecology of Vinnytsia National Medical University named after M.I. Pirogov Konkov Dmitry Gennadievich drew attention to the prevalence and main symptoms of climacteric syndrome in women. Special attention in the section on drug therapy of this condition was paid to the use of the drug VALARGIN. The author took as a basis a clinical study in which the state of microcirculation was determined in women with clinical manifestations of climacteric syndrome and the effectiveness of Valargin - high-dose oral L-arginine (3000 mg) was evaluated.

Two groups of patients were recruited in the study:

Main group: patients 40-50 years old (mean age 46.3±0.7) with clinical manifestations of climacteric syndrome of mild and moderate severity in the amount of 30 women.

Control group: patients aged 40-50 years without manifestations of climacteric syndrome in the amount of 32 women. Valargin was prescribed 1 tablet (3000 mg) 1 time per day for 1 month to all patients of the main group in order to correct endothelial dysfunction.

During the study, a significant correlation was found between the level of estrogens in women with climacteric syndrome and the index of endothelial cell activity.

The use of Valargin at a dose of 3000 mg (1 tab. per day) for 1 month significantly improves the index of endothelial cell activity by 34%.

The main results of the study are that the use of Valargin at a dose of 3000 mg (1 tab. per day) for 1 month significantly reduces the clinical manifestations of climacteric syndrome: the degree of its severity on the MRS scale decreased from 14.7±1.5 to 8.6±1.5 - by 42%.

Valargin contains a high dose of pure L-arginine - 3000 mg (without salt residue, free L-arginine), which ensures the effectiveness of the drug in endothelial dysfunction

Valargin is available in a convenient form of effervescent tablets and is used only once a day.

European quality: country of manufacture Germany (SUNLIFE Produktions, Germany).